-
Mashup Score: 1SIMPLIFY-1: Momelotinib Leads to Higher Transfusion Independence in MF | Blood Cancers Today - 4 day(s) ago
Momelotinib achieved higher rates of transfusion independence compared with ruxolitinib.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2Epcoritamab Produces Promising Responses in Patients With Follicular Lymphoma | Blood Cancers Today - 4 day(s) ago
Subcutaneous epcoritamab monotherapy yielded deep responses with promising response rates in high-risk relapsed or refractory follicular lymphoma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Molly Stoddart, RN, BSN, on Clinical Research Nursing in Multiple Myeloma | Blood Cancers Today - 4 day(s) ago
Molly Stoddart, RN, BSN, a clinical research nurse on the multiple myeloma team at the Winship Cancer Institute at Emory, shares her experiences.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 24Subscribe | Blood Cancers Today - 5 day(s) ago
Sign up for Blood Cancers Today eNewsletters to join an extensive community of hematologic oncology professionals and get the latest news and insights from the field.
Source: bloodcancerstoday.comCategories: General Medicine News, Hematologists1Tweet
-
Mashup Score: 7Mosunetuzumab Continually Shows Safety, Efficacy in Relapsed or Refractory Follicular Lymphoma | Blood Cancers Today - 6 day(s) ago
Intravenous mosunetuzumab was administered in 21-day cycles, with step-up dosing integrated in cycle one.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
Prefibrotic myelofibrosis is the focus of βSOHO State of the Art Updates and Next Questions.β
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Indolent B-Cell Lymphoma | Blood Cancers Today - 7 day(s) ago
Indolent B-cell lymphoma consists of slow-growing non-Hodgkin lymphomas that form in B cells, including follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 14FLT3 Gene Cluster Expression, Not FLT3 Mutation Status Predicts Quizartinib Response in AML | Blood Cancers Today - 7 day(s) ago
Benefit from treatment with quizartinib was accurately predicted by a βFLT3-likeβ gene expression signature identified in patients with acute myeloid leukemia.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Treatment benefit from the FLT3 inhibitor quizartinib was predicted by a βFLT3-likeβ gene expression signature identified in patients with #AML both with and without FLT3 mutations, according to a study led by @MosqueraOrgeira of @UniversidadeUSC. π https://t.co/8zCXWlajcx https://t.co/a3rVPvm68N
-
-
Mashup Score: 11What are the Treatment Options for Patients With Lenalidomide-Refractory Myeloma? | Blood Cancers Today - 8 day(s) ago
Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 33
Alan Skarbnik, MD, and Manni Mohyuddin, MBBS, discuss the concept of MRD in hematologic malignancies.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
β Momelotinib achieved higher rates of transfusion independence and reduced transfusion intensity over time than ruxolitinib in patients with #myelofibrosis. π The study was led by @Vikas_Gupta_1, of @pmcancercentre. π Read more: https://t.co/tg6HIfifkR https://t.co/IjACvhSqSV